S100β protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma

Melanoma Research

Volumn 14, Issue 3, 2004, Pages 211-215

  Schmidt, Henrik ^a   Sorensen, Boe S ^a   Nexo, Ebba ^a   Von Der Maase, Hans ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Immunotherapy; Metastatic melanoma; Predictive factors; S100 protein; Treatment monitoring

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; HISTAMINE; PROTEIN S100B; RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2; PROTEIN S 100; S100A1 PROTEIN;

AMELANOTIC MELANOMA; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MONITORING; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN METASTASIS; ADULT; AGED; BLOOD; CLINICAL TRIAL; DISEASE COURSE; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; S100 PROTEINS; TREATMENT OUTCOME;

EID: 3042828886     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000129378.99270.f5     Document Type: Article

References (17)

1. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 (suppl 1):S11-S14.
2. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228:307-319.
3. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73:629-636.
4. Moore BW. Chemistry and biology of the S-100 protein. Scand J Immunol Suppl 1982; 9:53-74.
5. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57:3149-3153.
6. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72:3091-3098.
7. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, Hansson J. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19:824-831.
8. Schmidt H, Geertsen PF, Fode K, Rytter C, Bastoholt L, von der Maase H. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study. Melanoma Res 2000; 10:66-77.
9. Schmidt H, Larsen S, Bastholt L, Fode K, Rytter C, von der Maase H. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Ann Oncol 2002; 13:1919-1924.
10. Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 1998; 77:2210-2214.
11. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
12. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology 1997; 194:208-212.
13. Schultz ES, Diepgen TL, Von Den DP. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998; 138:426-430.
14. Hauschild A, Engel G, Brenner W, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999; 140:1065-1071.
15. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003; 13:45-49.
16. Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer 2001; 94:586-590.
17. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921-2929.